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Abstract
Background—Psychosis prevention and early intervention efforts in schizophrenia have focused 
increasingly on sub-threshold psychotic symptoms in adolescents and young adults. Although 
many youth report symptom onset prior to adolescence, the childhood incidence of prodromal-
level symptoms in those with schizophrenia or related psychoses is largely unknown.
Methods—This study reports on the retrospective recall of prodromal-level symptoms from 40 
participants in a first-episode of schizophrenia (FES) and 40 participants at “clinical high risk” 
(CHR) for psychosis. Onset of positive and non-specific symptoms was captured using the 
Structured Interview for Prodromal Syndromes. Frequencies are reported according to onset 
during childhood (prior to age 13), adolescence (13–17), or adulthood (18 +).
Results—Childhood-onset of attenuated psychotic symptoms was not rare. At least 11% of FES 
and 23% of CHR reported specific recall of childhood-onset of unusual or delusional ideas, 
suspiciousness, or perceptual abnormalities. Most recalled experiencing non-specific symptoms 
prior to positive symptoms. CHR and FES did not differ significantly in the timing of positive and 
non-specific symptom onset. Other than being younger at assessment, those with childhood onset 
did not differ demographically from those with later onset.
Conclusion—Childhood-onset of initial psychotic-like symptoms may be more common than 
previous research has suggested. Improved characterization of these symptoms and a focus on 
their predictive value for subsequent schizophrenia and other major psychoses are needed to 
facilitate screening of children presenting with attenuated psychotic symptoms. Accurate detection 
of prodromal symptoms in children might facilitate even earlier intervention and the potential to 
alter pre-illness trajectories.
Keywords
Child; Psychosis; Psychotic-like; SIPS; Prodrome; Early onset
1. Introduction
Schizophrenia and related psychotic disorders are serious disorders that can lead to long-
term disability, particularly if untreated (Keshavan et al., 2003; Marshall et al., 2005; Frazier 
et al., 2007). Over the past 50 years, significant research effort has focused on the early 
detection of emerging psychosis in order to facilitate the identification of etiological 
mechanisms and earlier intervention. The examination of familial risk, based on presumed 
genetic contribution to psychotic disorders and accompanying neurodevelopmental markers, 
has made important progress (Keshavan et al., 2005). In recent years, efforts have expanded 
to consider clinical and behavioral high risk as well as familial risk, determined through 
symptom-based screening instruments such as the Structured Interview for Prodromal 
Syndromes (SIPS, Miller et al., 1999; McGlashan et al., 2001). These instruments query the 
onset and severity of newly emerging or worsening symptoms that may suggest a possible 
prodrome to, or more conservatively “clinical high risk” (CHR) for, a psychotic disorder.
Most primary psychotic disorders onset in late adolescence and early adulthood, with peak 
onset between ages 15 to 25 in males and 20 to 29 in females (Castle et al., 1993; Häfner et 
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al., 1993). Since the prodromal period is thought to precede illness onset by 1 to 6 years 
(Yung and McGorry, 1996; Häfner et al., 1998; Köhn et al., 2004), screening measures for 
identification of prodromal symptoms have been developed primarily for adolescents and 
young adults. The predictive validity of attenuated psychotic symptoms in younger cohorts 
has yet to be determined. Given the developmental normalcy of magical thinking, grandiose 
and fantastical beliefs, concrete and more loosely organized thinking in young children, and 
the lower frequency of truly psychotic thinking, child responses to adolescent and adult 
screening instruments should be interpreted with caution (e.g., Woolley et al., 2004; Bartels-
Velthuis et al., 2011). Poorly worded questions that exceed a child’s comprehension can 
result in false positives (Breslau, 1987). That said, even carefully conducted screening and 
interviews have yielded high frequencies of psychotic-like experiences in children.
Indeed, Laurens et al. (2012) found that in a London community sample of 8000 children 
ages 9–11, almost two-thirds endorsed at least one “psychotic-like experience” (PLE). In a 
study by Yoshizumi et al. (2004), 21% of a Japanese general population sample of children 
ages 11–12 experienced hallucinations. Subgroups that experience PLEs in general adult 
populations share biological and environmental risk factors with schizophrenia (Kelleher et 
al., 2011a), suggesting a continuum of psychosis in the general population (van Os et al., 
2008). Subclinical auditory hallucinations in childhood appear to be transitory in most cases, 
but similarly to PLEs in adults, correlate with developmental and behavioral problems, 
hinting that such a continuum may also be present in youth populations (Hlastala and 
McClellan, 2005; Bartels-Velthuis et al., 2010, 2011). Thus, accumulating evidence suggests 
that PLEs may be more common in childhood than previously recognized. Importantly, 
prevalence of PLEs does not equate with prevalence of prodromal syndromes. There is poor 
reliability between PLEs and prodromal syndromes identified through structured clinical 
interview with the SIPS and much lower prevalence rates of CHR syndromes relative to 
PLEs in both adults and children (Kelleher et al., 2011a, 2011b; Schultze-Lutter et al., 2013, 
2014).
Childhood-onset schizophrenia is exceedingly rare, with an estimated prevalence rate of 
1.8/10,000 (Häfner and Nowotny, 1995). Yet genetic, neuroanatomical, cognitive, motor, 
and social abnormalities during childhood have been repeatedly associated with adult onset 
of schizophrenia (Jones et al., 1994; Marenco and Weinberger, 2000; Rapoport et al., 2005; 
Woodberry et al., 2008; Thermenos et al., 2013). In retrospective research of the precursors 
to schizophrenia, Häfner et al. (1998) found that negative symptoms preceded positive 
symptoms in 70% of adult-onset cases. However, these early “premorbid” and “prodromal” 
abnormalities and symptom patterns tend to be nonspecific, associated with risk for mood 
disorders like depression or bipolar disorder as well as psychosis (Cannon et al., 1997; van 
Os et al., 1997). A better understanding of the predictive value of psychotic-like experiences 
(PLEs) during childhood may improve the specificity of risk identification in childhood 
cohorts and support earlier intervention efforts.
One strategy for understanding the potential implications of psychotic-like experiences in 
children is to identify the degree to which individuals with clinically significant psychotic-
like symptoms or psychotic disorders report a childhood onset of these symptoms. Thus, the 
purpose of the current study was to identify the prevalence and pattern of prodromal-level 
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symptom onset in childhood as reported by adolescents and adults either in a first episode of 
schizophrenia (FES) or with a CHR syndrome. Although we explored differences in 
childhood symptom onset between these two groups, the overall goal was to characterize 
childhood symptom onset in both groups to inform screening and early intervention efforts. 
To our knowledge, no previous studies have used the same method to query symptom onset 
in both groups.
2. Methods
2.1. Participants
The study sample was recruited for the Boston Center for Intervention Development and 
Applied Research (CIDAR) study entitled, “Vulnerability to Progression in Schizophrenia” 
(www.bostoncidar.org). Individuals ages 13–45 in a first episode of schizophrenia (FES, 
including schizophrenia, schizoaffective disorder, or schizophreniform disorder) or persons 
ages 13–35 meeting criteria for CHR were recruited from area hospitals, outpatient 
treatment settings, and the metropolitan Boston community through advertisements, formal 
outreach presentations, and word of mouth. Exclusion criteria included sensory-motor 
handicaps, neurological disorders, medical illnesses that significantly impair neurocognitive 
function, intellectual disability, education less than 5th grade if under 18 or less than 9th 
grade if 18 or older, lack of English fluency, DSM-IV-TR substance abuse in the past month 
or substance dependence, excluding nicotine, in the past 3 months, current suicide risk, and 
a history of electroconvulsive therapy within the prior 5 years.
CIDAR recruited a total of 44 FES and 45 CHR participants. Of these, we excluded from 
these analyses one CHR and four FES due to missing SIPS data, one CHR (from the CHR 
sample only) who converted to schizophrenia and was thus included in the FES sample, and 
three CHR who had no reported attenuated positive symptom onset (but were included in the 
CIDAR study on the basis of a presumed negative symptom syndrome or genetic risk and 
decline of functioning). Thus 40 CHR and 40 FES were included in these analyses. All 
participants provided written informed consent (or assent and parental consent in the case of 
minors). The institutional review boards at the Beth Israel Deaconess Medical Center, 
Cambridge Health Alliance, Harvard Medical School, Massachusetts General Hospital, the 
Veteran Affairs Boston Healthcare System, Brockton campus, and Brigham and Women’s 
Hospital approved the study.
2.2. Clinical measures and procedures
FES status and clinical diagnoses for both groups were determined by diagnostic consensus 
based on a clinical interview with the Structured Clinical Interview for DSM IV-TR (SCID, 
Research Version, First et al., 2002) and available medical records. Prodromal symptoms 
and symptom onset were assessed with the Structured Interview of Prodromal Syndromes 
(SIPS; Miller et al., 1999; McGlashan et al., 2001; see von Hohenberg et al., 2013 for details 
on CHR criteria used in the CIDAR study). All clinical interviewers were trained on the 
SIPS by Yale University trainers (Drs. Tandy Miller and/or Barbara Walsh), and had to 
achieve accurate identification of CHR status for two videotaped interviews. Final 
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determination of CHR status was determined by diagnostic consensus based on the Criteria 
of Prodromal Syndromes (COPS).
For inclusion in these analyses, participants had to provide sufficient recall of positive 
(attenuated psychotic) and nonspecific (negative, disorganized, or general) symptom onset 
via the 19 item SIPS (see Supplemental Table 1). For CHR participants the SIPS was the 
primary clinical interview for determining both eligibility and onset of PLEs. For FES 
participants the SIPS was a secondary interview, eliciting retrospective account of the onset 
of prodromal-level symptoms both for symptoms that had subsequently reached a psychotic 
level and for symptoms currently experienced at a “prodromal-level.” Based on the 
difficulty eliciting retrospective self-report of symptom onset for which acutely psychotic 
patients might have little or no insight (e.g., P3 grandiosity and P5 disorganized speech), the 
CIDAR study decided to query only nine of the nineteen symptoms of the SIPS Version 4.0 
in FES patients (see Supplemental Table 1). Only participants with data on at least 8 of these 
9 symptoms, including an estimated onset date for at least one symptom in each symptom 
group (positive, nonspecific) reported to be in the prodromal range, were included.
Parental socioeconomic status was determined by the Hollingshead scale (Hollingshead, 
1975), using occupational and income data from both parents whenever possible. The 
Wechsler Abbreviated Scale of Intelligence (WASI, Wechsler, 1999) and the Wide Range 
Achievement Test-4 (WRAT4, Wilkinson and Robertson, 2006) Word Reading subtest were 
administered to all participants by trained research assistants, as part of a comprehensive 
neuropsychological battery. Similarly, two measures of functioning, the Global Functioning: 
Social and Role scales (Cornblatt et al., 2007) were administered to all participants by 
clinicians trained on these measures by the instrument developers.
2.3. Establishing age of onset
Consistent with standard administration of the SIPS, participants were asked to identify or 
estimate the date of onset of any symptom (positive or nonspecific) endorsed at a putatively 
prodromal level (rating ≥ 3). Childhood-onset was defined as onset prior to age 13. 
Adolescent onset was defined by onset between ages 13–17. Adult onset was defined as 
onset at or after age 18. Onsets that could not be clarified beyond, “as long as I can 
remember” or “my entire life” were coded as “Lifetime” and, when included in analyses, 
included as “childhood-onset.” Clinicians documented the onset as “could not be 
determined” when participants could not provide a reliable estimate. Hospitalization, prior 
assessment records, or parental reports were sometimes requested for diagnostic 
clarification. In a few cases, information from these sources was incorporated in estimating 
the developmental period of symptom onset. To account for the quality of data available, we 
reported the frequency of childhood-onset of positive symptoms separately 1) using only 
symptoms queried in both groups for which estimated onset dates were available, 2) also 
including symptoms queried in both groups and reported as present during the person’s 
entire “lifetime,” and 3) also including onset of grandiosity and disorganized communication 
(for CHR and one FES for whom the latter was the only positive symptom) and onset of 
acute psychosis for two FES with no preceding period of attenuated positive symptoms (see 
Table 2).
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2.4. Statistical analyses
We conducted data analyses in SPSS version 18. We tested between group differences of 
parametric continuous data with independent samples t tests and repeated measures 
ANOVAs and repeated the ANOVAs covarying for age, given group differences. We tested 
between group differences of non-parametric, ordinal, or categorical data with Chi-square, 
Fisher’s exact, and Mann-Whitney U tests as appropriate.
3. Results
3.1. Sample characteristics
As is shown in Table 1, both FES and CHR samples were racially diverse (37–45% non-
Caucasian), with a slightly higher proportion of males, and estimated IQon the higher end of 
the average range. On average, participants had at least a high school education. Except for 
age and percent Hispanic/Latino (the FES sample was older, as expected, with a higher 
percentage of Hispanic participants), groups did not differ significantly on demographic 
variables.
FES participants met DSM-IV-TR criteria for schizophreniform disorder (n = 4, 10%), and 
schizoaffective disorder, bipolar type (n = 5, 13%) and depressed type (n = 9, 23%), and 
schizophrenia, disorganized type (n = 2, 5%), paranoid type (n = 11, 28%), and 
undifferentiated type (n = 9, 23%). Thirty-six (90%) of CHR participants met criteria for at 
least one DSM-IV-TR Axis I diagnosis, with many meeting criteria for multiple comorbid 
Axis I disorders. These included anxiety (n = 22, 55%), depressive (n = 16, 40%), 
behavioral (n = 9, 23%), bipolar (n = 9, 23%), developmental (n = 2, 5%), eating (n = 2, 
5%), pain, (n = 1, 3%), and dissociative disorders (n = 1, 3%).
3.2. Frequency of childhood-onset of attenuated psychotic symptoms
Participant recall in response to SIPS queries suggested that childhood-onset of attenuated 
psychotic symptoms was not rare (see Table 2). Using all available data, nearly one-fifth of 
FES participants and over one-third of CHR identified initial onset of attenuated positive 
symptoms in childhood. Even excluding symptoms that people reported experiencing as 
long as they could remember (“lifetime” onset), 11% of FES and 23% of CHR reported 
childhood-onset of positive symptoms. The two groups did not differ significantly in rates of 
childhood-onset (χ2(1) = 1.03, p = 0.23, including “lifetime”; χ2(1) = 1.87, p = 0.14, 
excluding “lifetime”).
3.3. First symptoms recalled
We examined whether participants recalled first experiencing positive or non-specific 
symptoms (see Fig. 1). Overall, more individuals identified experiencing non-specific 
symptoms (negative, disorganized, or general symptoms) before positive symptoms (unusual 
thought content, suspiciousness, perceptual abnormalities) in both groups. A few identified 
simultaneous onset of positive and non-specific symptoms (see also Supplemental Table 2).
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3.4. Timing of onset of initial symptoms including non-specific symptoms
When age of onset of both positive and non-specific symptoms was considered, CHR and 
FES groups reported significantly different rates of first symptom onset by developmental 
period (see Table 3). Similar numbers of CHR participants identified childhood-onset as 
adolescent-and adulthood-onset, but with nearly half identifying childhood-onset of at least 
one symptom and a third or less reporting first symptom onset in adulthood. By contrast, 
nearly half of FES participants reported adult onset of positive and non-specific symptoms, 
although over a third of FES identified childhood-onset of at least one symptom.
3.5. Positive symptom onset by specific symptom
Some childhood-onset was reported for all positive (P) symptoms, with the frequencies of 
specific P symptom onset by developmental period shown in Fig. 2. There was no evidence 
that childhood-onset was specific to one type of positive symptom (e.g., hallucinations). 
Both groups reported the highest frequency of P symptom onset in adulthood, with the 
exception of unusual thought content (P1) in CHR. However, there were no statistically 
significant differences by group or symptom in developmental period of onset. Childhood-
onset of grandiosity (P3) was reported by only one CHR individual.
3.6. Demographics of childhood vs. later onset of positive symptoms
Overall, individuals reporting childhood-onset of positive symptoms did not differ 
significantly on gender, race, ethnicity, social, role, or global functioning, or estimated IQ 
(Wechsler Abbreviated Scale of Intelligence, Wechsler, 1999, or single word reading 
measured by the Wide Range Achievement Test 4, Word Reading, Wilkinson and 
Robertson, 2006) from those who reported later onset. However, those with childhood onset 
of positive symptoms were significantly younger at the time of assessment (t = 2.02, p = 
0.047) and had completed less education (t = 2.07, p = 0.042). The difference in age was not 
significant for either CHR or FES group alone, although the CHR group showed the 
strongest trend for younger age in those reporting childhood positive symptom onset. CHR 
reporting childhood-onset based on all 5 positive symptoms were significantly younger than 
those reporting later onset (t = 2.45, p = 0.019). This group was also predominantly male (11 
of 14, χ2(1) = 5.87, p = 0.015) and had higher total positive symptom scores on the SIPS 
(13.9 vs. 11.5, F[1,39] = 4.31, p = 0.045). The FES participants with childhood-onset 
differed from FES with later onset only in Global Assessment of Functioning scores (40.7 
vs. 51.3, respectively, F[1,37] = 4.91, p = 0.033).
4. Discussion
The purpose of this study was to examine the frequency of childhood-onset of attenuated 
psychotic symptoms in adolescents and adults identified with FES or CHR syndromes. In 
contrast to a significant literature suggesting that childhood-onset of psychotic and 
psychotic-like symptoms is rare even in schizophrenia samples (e.g., Thomsen, 1996), 11–
19% of the FES sample and 23–35% of the CHR sample reported childhood-onset of 
attenuated psychotic symptoms. These higher rates are more consistent with the emerging 
literature from recent epidemiological and longitudinal birth cohort studies that suggest that 
PLEs may not only be relatively common in children ages 11–13, but that PLEs reported at 
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age 11 signal substantially increased risk of schizophreniform disorder (and not mood 
disorders) at age 26 (Poulton et al., 2000; Kelleher et al., 2011a, 2011b). Whereas the rates 
of childhood-onset of prodromal-level psychotic symptoms reported by FES may be more 
directly relevant to understanding precursors specific to schizophrenia than those reported 
by CHR, these latter rates support the association of attenuated psychotic symptoms in 
childhood with increased risk for a psychotic disorder, including non-schizophrenia 
psychoses and schizophrenia spectrum disorders.
The pattern of positive relative to non-specific symptom onset is also informative in 
understanding pathways to schizophrenia and psychosis more broadly. Although roughly 
half of both FES and CHR participants reported the onset of non-specific symptoms prior to 
the onset of positive symptoms, another half reported onset of positive symptoms either 
prior to or simultaneously with the onset of non-specific symptoms. This frequency appears 
to be higher than in prior reports (e.g., Häfner et al., 1998). The difference may reflect 
differences in sample selection and diagnostic criteria, the type of symptom queries (e.g., 
SIPS probes used in this study are designed to elicit prodromal as well as psychotic 
symptoms), and/or the degree to which family observations were solicited and included in 
estimating onset (these were systematically solicited in the Häfner study, but not in this 
study). Self-report of internal states is likely to differ from observable behavior or inferred 
changes for a number of reasons, including the degree of participant self-understanding 
and/or self-disclosure, the quality of family observation, and the quality and reliability of 
both participant and family recall.
For decades, clinical case report and research into the etiology of schizophrenia have 
identified a number of warning signs already evident during childhood, long before the onset 
of acute psychosis (e.g., Sullivan, 1927; Alaghband-Rad et al., 1995; Catts et al., 2013; 
Seidman et al., 2013). Yet the fact that these early signs have been largely non-specific to 
psychosis outcomes has limited their utility for prospectively identifying children at highest 
risk for serious mental illness. The extent of attenuated positive symptom onset during 
childhood associated with later schizophrenia raises the possibility of improved childhood 
detection, and with it the possibility for enhanced and timelier protective interventions. 
Research highlighting the long delays between psychosis onset and treatment, the 
association of delays to poorer outcome, and the potential of earlier intervention to improve 
outcomes is motivating early identification efforts and service system reforms worldwide 
(McGorry et al., 2003; Frazier et al., 2007; Lloyd-Evans et al., 2011; Fusar-Poli et al., 2012). 
Of course, additional prospective and retrospective research studies are needed to confirm 
these findings and their relevance to these efforts.
The findings reported here, in conjunction with research suggesting that childhood psychotic 
symptoms may be both heritable and associated with non-specific problems typical of 
psychotic illnesses (Polanczyk et al., 2010), support the need to expand psychosis risk 
assessment to children under the age of 13 (e.g., Kelleher et al., 2011a; Fux et al., 2013). 
Based on the age distributions of initial positive symptom onset (see Supplemental Fig. 1), 
screening children ages 10–12 might be particularly fruitful. In addition to specialized 
psychosis risk screening, standard childhood behavior screening instruments might be 
improved by including items that capture these experiences. Greater clarification of 
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population base rates and the predictive values of different symptoms and symptom 
combinations will be needed to balance the benefits and risks of such an effort.
For instance, recent studies of children in Ireland and Greater London found that children’s 
questionnaire endorsement of hallucinations (e.g., “yes, definitely” to the question “Have 
you ever heard voices or sounds that no one else can hear?”) was associated most closely 
with a latent psychosis construct, and had the highest predictive power for psychotic-like 
symptoms on interview (Kelleher et al., 2011a; Laurens et al., 2012). Yet, the retrospective 
report of symptoms by FES participants in the current study suggests that their childhood 
experience of attenuated psychotic symptoms was not dominated by hallucinatory 
experiences; delusional and persecutory ideas were just as common. The specificity of 
queries (e.g., probing a wide enough range of delusional ideas), varying capacities for self-
reflection, particularly with age, and the differences between prospective and retrospective 
judgments of the uniqueness of one’s experience are all likely to play a role in evaluating the 
significance and predictive value of symptom reports.
4.1. Limitations
The primary limitation of this study is its reliance on retrospective self-report, with its well-
known vulnerability to low reliability and validity and the influence of current mood and 
contextual factors (Brewin et al., 1993; Hardt and Rutter, 2004). It is worth noting, however, 
that studies of retrospective recall in women with schizophrenia found a bias toward under- 
rather than over-reporting of past events (obstetric complications, Buka et al., 2000), 
suggesting caution in assuming that self-reports err in the direction of over-reporting. 
Moreover, there is evidence that lack of reliability of retrospective self-reports in the context 
of psychopathology has been exaggerated (Brewin et al., 1993). Importantly, self-report 
remains the only measure of internal experiences such as mild delusional beliefs or odd 
perceptual experiences.
Another limitation is the lack of established reliability or validity in the use of the SIPS for 
eliciting retrospective recall of prodromal symptoms in a FES sample. Gauging when a 
symptom reached a prodromal level is particularly challenging with individuals who have 
limited insight into their symptoms, both current and past. This challenge also contributes to 
a significant amount of missing data, including dates that “could not be determined,” and 
symptoms that were queried for CHR but not FES participants. Although CHR and FES 
counts were compared only for symptoms queried in both samples, the lack of data on the 
onset of some symptoms, such as grandiosity and disorganized communication, in FES may 
contribute to an underestimate of childhood symptom onset in this sample. The fact that 
younger participants reported higher rates of childhood psychotic-like symptoms might 
simply reflect an association between earlier symptom onset with earlier detection and 
referral. It might also speak to easier recall of childhood in adolescents than adults (e.g., 
Rubin and Schulkind, 1997) or reflect higher levels of insight into the nature of their 
experiences. Alternatively, childhood onset of positive symptoms may be a more common 
precursor to non-schizophrenia psychosis than schizophrenia, and thus be more frequent in 
the younger and more diagnostically inclusive CHR sample than the FES sample. 
Methodologically sound longitudinal studies obtaining both prospective and retrospective 
Woodberry et al. Page 9
Schizophr Res. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
reports of childhood PLEs are needed to better clarify the relationship between symptom 
onset, help-seeking, referral patterns, and diagnostic and functional outcomes.
Although clinicians took available parental observations and medical record reports into 
account in estimating symptom onsets, this was not conducted in a systematic way or for all 
participants. To account for this, we reported the frequency of childhood-onset of positive 
symptoms separately according to three different methods of counting (see Methods and 
Table 2). Finally, without long-term follow-up data, the degree to which the CHR 
participants were clinically comparable to the FES participants during a prodromal phase is 
unknown.
4.2. Conclusion
The knowledge that a substantial minority of individuals with schizophrenia and enhanced 
risk for major psychotic disorders report childhood-onset of psychotic-like symptoms may 
prompt a pediatrician or school psychologist to seek specialized consultation for a 10 year 
old with mild but developmentally atypical delusional thinking or suspiciousness of others. 
More broadly, we hope this knowledge will prompt further development of psychosis-
screening questions and strategies in children. Given the higher frequency in children than in 
adolescents and adults of at least some psychotic-like symptoms, attention and response to 
these symptoms will require sensitivity to a number of developmental issues. These include 
the role of cognitive and language development in the recognition and reporting of 
symptoms (e.g., Caplan et al., 2000), base rates of different symptoms in clinical and general 
populations at different ages, and the reliability and validity of different screening questions, 
self-report measures, and child and parent interviews for eliciting and distinguishing 
symptoms of concern from benign childhood experience. The ultimate goal is the 
development of age-appropriate interventions that maximize protective factors (e.g., stress-
reduction) while minimizing stigma, side effects, hopelessness, and other potential negative 
consequences.
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Fig. 1. 
Initial symptom onset. Number and percent of each sample for whom the indicated symptom 
type was experienced first. Only the 9 SIPS symptoms are included (when all19 symptoms 
are included, for CHR participants only, CHR percentages change to 55% non-specific and 
10% simultaneous.).
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Fig. 2. 
Frequency of onset by specific positive symptom and age group. Individuals are counted 
multiple times if they endorsed multiple P symptoms. “Lifetime” onset was counted as 
childhood-onset. Groups did not differ significantly in developmental period of onset for any 
P symptom.
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Table 1
Sample characteristics.
CHR (n = 40) FES (n = 40)
Mean (SD) Mean (SD) Test statistic p
Age 19.8 (3.8) 21.9 (4.5) t(48) = −2.25 0.03
Years of education 12.5 (2.8) 13.2 (2.6) t(78) = 1.13 0.26
WASI 113.4 (14.8) 109.8 (12.9) t(78) = 1.09 0.28
WRAT-4 reading 110.2 (16.5) 110.7 (16.6) t(78) = −0.13 0.90
n (%) n (%) Test statistic p
Male 21 (52) 27 (68) χ2(1) = 1.88 0.17
Caucasian 22 (55) 25 (63) χ2(1) = 0.46 0.50
Hispanic or Latino 2 (5) 8 (20) FET = 0.09 0.04
Median, mean
(SD)
Median, mean
(SD)
PSES 2, 2.10 (1.03) 2, 2.42 (1.13) U = 664 0.17
CHR = clinical high risk; FES = first episode schizophrenia; WASI = Wechsler Abbreviated Scale of Intelligence (current IQ estimate based on 
Vocabulary and Block Design subtests); WRAT-4 = Wide Range Achievement Test-4 (premorbid IQ estimate based on Reading subtest); PSES = 
parental socioeconomic status, Hollingshead score (1–5 scale, 1 highest); FET = Fisher’s exact test; U = Mann–Whitney U test. Tests significant at 
p < 0.05 are in bold. Groups did not differ on education or IQ estimate even when age was included as a covariate.
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Table 2
Frequency of initial positive symptom onset by age.
Based on onset date (39 CHR, 35 
FES)
Including “lifetime” onset (39 
CHR, 37 FES)
Based on all available data (40 
CHR, 40 FES)
CHR Childhood 9 (23.1%) 11 (28.2%) 14 (35.0%)
Adolescence 15 (38.5%) 14 (35.9%) 14 (35.0%)
Adulthood 15 (38.5%) 14 (35.9%) 12 (30.0%)
FES Childhood 4 (11.4%) 7(18.9%) 7 (17.5%)
Adolescence 11 (31.4%) 10 (27.0%) 12 (30.0%)
Adulthood 20 (57.1%) 20 (54.1%) 21 (52.5%)
Chi-square 3.045, p = 0.218 2.564, p = 0.278 4.942, p = 0.085
CHR = clinical high risk; FES = first episode schizophrenia. Counts for first two columns are based only on the 3 positive symptoms consistently 
queried in both groups: unusual thought content (P1), suspiciousness/persecutory ideas (P2), and perceptual abnormalities (P4); based on onset 
date: count based only on symptoms for which a date of onset could be estimated; including “lifetime” onset: counts include P1, P2, and P4 onsets 
reported as “Lifetime” or “As long as I can remember” as childhood-onsets; based on all available data: counts include grandiosity (P3) and 
disorganized communication (P5) onset data for CHR, age of onset of fully psychotic symptoms in the case of FES reporting no period of 
attenuated positive symptoms/prodrome, and one FES reporting the only positive symptom to be disorganized speech (P5) that onset in adulthood. 
There were no significant group differences in distributions by developmental period.
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Table 3
Timing of initial positive and non-specific symptom onset.
Positive symptoms (39 CHR, 37 
FES)
Non-specific symptoms (38 CHR, 
37 FES)
First symptom (either) (40 CHR, 
40 FES)
CHR Childhood 11 (28.2%) 14 (38.9%) 19 (47.5%)
Adolescence 14 (35.9%) 13 (36.1%) 14 (35.0%)
Adulthood 14 (35.9%) 9 (25.0%) 7 (17.5%)
FES Childhood 7(18.9%) 13 (35.1%) 15 (37.5%)
Adolescence 10 (27.0%) 8 (21.6%) 8 (20.0%)
Adulthood 20 (54.1%) 16 (43.2%) 17 (42.5%)
Chi-Square 2.564, p = 0.278 3.174, p = 0.204 6.274, p = 0.043
CHR = clinical high risk; FES = first episode schizophrenia. Counts represent the frequency of participants for whom the given symptom type was 
reported to have onset within the specified developmental stage (counting only 9 core SIPS symptoms for the first two columns and in column 3, 
including all 19 symptoms for CHR and acute and P5 onset for FES). “Lifetime” onsets counted as childhood for all columns. Twenty-six (65%) of 
FES and 20(50%) of CHR reported positive and non-specific symptom onsets within the same developmental period. Differences in distributions 
by group of p < 0.05 are in bold.
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